relacorilant
relacorilant: sourced relationships with 1 company · 8 clinical trials tracked · 1 FDA decision.
relacorilant evidence translation
What we can confirm
1 FDA record · 8 tracked trials
What it means
What to watch
Prepared research question
How could relacorilant → CORT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CORCEPT THERAPEUTICS INC (CORT) Reported 2026-03-25 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (8)
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
Primary endpoint: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1)
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
Primary endpoint: Progression-Free Survival (PFS)
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Primary endpoint: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant
Primary endpoint: Change in Average 24-hour SBP
A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary endpoint: Progression-free Survival (PFS)
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Primary endpoint: Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase.
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
Primary endpoint: Long-term safety of relacorilant
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with relacorilant?
relacorilant has dated SEC/FDA relationship records for CORCEPT THERAPEUTICS INC.
How many clinical trials involve relacorilant?
BioSniper tracks 8 clinical trials involving relacorilant.
What is relacorilant's latest FDA decision?
The most recent tracked FDA decision for relacorilant is Approval for 1 INDICATIONS AND USAGE LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )] . LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. ( 1 , 14 ), dated March 25, 2026.